Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Autoimmune Disorders

Free Subscription 13.10.2025 1 Ann Neurol 2 Brain 1 Diabetes 2 Intern Med 2 J Nephrol 2 J Neurol 2 J Pediatr Endocrinol Metab 3 Lancet 9 Mult Scler 1 Nat Rev Neurol 2 Neurologia (Engl Ed) 2 Neurology 4 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Neurol

1. SIMPSON-YAP S, Morwitch E, Tanner SA, Thomson SM, et al
   Epstein-Barr Virus, Lower Vitamin D, Low Sun Exposure, and HLA-DRB1*1501 Risk Variant Share Common Epigenetic Pathways Leading to Multiple Sclerosis Onset.
   Ann Neurol. 2025 Oct 10. doi: 10.1002/ana.78043.
   PubMed         Abstract available
   
   

   
   Brain

2. BELLANTI R, Iserte AC, Johnson CB, Goodfellow J, et al
   Enhanced adenoviral reactivity in Guillain-Barre syndrome after SARS-CoV-2 infection and vaccination.
   Brain. 2025 Oct 7:awaf376. doi: 10.1093.
   PubMed         Abstract available
   
   
3. MUKHERJEE T, McMurran CE, Holland J, Daruwalla C, et al
   Ageing and remyelination failure in people with multiple sclerosis.
   Brain. 2025 Oct 6:awaf373. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Diabetes

4. HAMPE CS, Kamat V, Bryan CL, Pyle L, et al
   Deleterious Effects of a GAD65 Monoclonal Autoantibody on Islet Function.
   Diabetes. 2025 Oct 10:db250475. doi: 10.2337/db25-0475.
   PubMed         Abstract available
   
   

   
   Intern Med

5. NAKAO Y, Kunieda J, Taguchi T, Tanaka Y, et al
   Delayed Therapeutic Response to Oral Corticosteroids and Rituximab Leading to Dialysis Independence in a Patient with Treatment-resistant C3 Glomerulonephritis.
   Intern Med. 2025 Oct 9. doi: 10.2169/internalmedicine.6219.
   PubMed         Abstract available
   
   
6. KAWAMURA Y, Mizumoto J, Minoda M, Fujimoto T, et al
   A Case of Anti-signal Recognition Particle Antibody-associated Myopathy with a Dermatomyositis-like Rash Successfully Treated for Concomitant Cardiac Involvement with Intravenous Immunoglobulin Therapy.
   Intern Med. 2025 Oct 9. doi: 10.2169/internalmedicine.5718.
   PubMed         Abstract available
   
   

   
   J Nephrol

7. DING Q, Xue C, Gao X, Tang X, et al
   Efficacy and safety of obinutuzumab on progressive IgA nephropathy: a case series.
   J Nephrol. 2025 Oct 9. doi: 10.1007/s40620-025-02423.
   PubMed         Abstract available
   
   
8. KASZYNSKA A, Kepska-Dzilinska M, Karakulska-Prystupiuk E, Perkowska-Ptasinska A, et al
   Kidney failure in the course of focal segmental glomerulonephritis in a patient after alloHSCT - a case study and review of the literature.
   J Nephrol. 2025 Oct 7. doi: 10.1007/s40620-025-02375.
   PubMed         Abstract available
   
   

   
   J Neurol

9. TUNC A, Koc ER, Carnero Contentti E, Gomez Figueroa E, et al
   Predictors of relapse and disability in NMOSD, MOGAD, and double-seronegative demyelinating syndromes: an international multicenter retrospective cohort study.
   J Neurol. 2025;272:680.
   PubMed         Abstract available
   
   
10. AHMAD R, Jackson-Tarlton CS, Flanagan EP, Messina S, et al
    Critical demyelinating lesions in progressive multiple sclerosis: a prospective observational study.
    J Neurol. 2025;272:677.
    PubMed         Abstract available
    
    

    
    J Pediatr Endocrinol Metab

11. NALLAPU C, Dayal D, Sachdeva N, Kumar M, et al
    Impact of high-dose vitamin D supplementation initiated shortly after diagnosis on residual beta cell function and partial remission rates in children with type 1 diabetes.
    J Pediatr Endocrinol Metab. 2025;38:1052-1058.
    PubMed         Abstract available
    
    
12. BIESTER T, Reschke F, Danne T, Julien M, et al
    A multi-stakeholder perspective on medical devices for children and adolescents with type 1 diabetes: huge unmet needs for the smallest.
    J Pediatr Endocrinol Metab. 2025;38:1001-1015.
    PubMed         Abstract available
    
    

    
    Lancet

13. FILIPPI M, Rocca MA
    MS-STAT2: lessons from negative trials in multiple sclerosis.
    Lancet. 2025 Oct 1:S0140-6736(25)01673-3. doi: 10.1016/S0140-6736(25)01673.
    PubMed        
    
    
14. ZIEGLER AG, Cengiz E, Kay TWH
    The future of type 1 diabetes therapy.
    Lancet. 2025 Sep 19:S0140-6736(25)01438-2. doi: 10.1016/S0140-6736(25)01438.
    PubMed         Abstract available
    
    
15. CHATAWAY J, Williams T, Blackstone J, John N, et al
    Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trial.
    Lancet. 2025 Oct 1:S0140-6736(25)01039-6. doi: 10.1016/S0140-6736(25)01039.
    PubMed         Abstract available
    
    

    
    Mult Scler

16. LANG MV, Welk GM, Tajfirouz DA, Chodnicki KD, et al
    Unveiling Misdiagnosis: Rethinking Seronegative NMOSD.
    Mult Scler. 2025;31:1381-1384.
    PubMed         Abstract available
    
    
17. HILL JB, Mastick ML, Chiong-Rivero H, Grebenciucova E, et al
    Characterizing financial toxicity among people living with neuromyelitis optica spectrum disorder.
    Mult Scler. 2025;31:1370-1380.
    PubMed         Abstract available
    
    
18. HAM AS, Gomez Hjerthen I, Tian DC, Gu H, et al
    Unemployment, work hour reduction, and income loss: An international, multicentered, cross-sectional study of neuromyelitis optica spectrum disorder.
    Mult Scler. 2025;31:1358-1369.
    PubMed         Abstract available
    
    
19. BALSHI A, Feldman TB, Dempsey JP, Baber U, et al
    A multicenter cohort of transgender and gender diverse people with multiple sclerosis.
    Mult Scler. 2025 Oct 8:13524585251383330. doi: 10.1177/13524585251383330.
    PubMed         Abstract available
    
    
20. BARBUTI E, Prosperini L, Ruggieri S, Haggiag S, et al
    How premorbid structural reserve affects disability accrual in multiple sclerosis.
    Mult Scler. 2025 Oct 8:13524585251372440. doi: 10.1177/13524585251372440.
    PubMed         Abstract available
    
    
21. FADDA G, Palace J
    ECTRIMS 2024 Lecture: Unraveling the spectrum of the antibody-mediated demyelinating diseases: Emerging insights.
    Mult Scler. 2025;31:1282-1293.
    PubMed         Abstract available
    
    
22. SUTHIPHOSUWAN S, Lim TR, Hu Z, Colak E, et al
    Choroid plexus enlargement correlates with demyelinating lesions and thalamic atrophy in radiologically isolated syndrome.
    Mult Scler. 2025;31:1314-1325.
    PubMed         Abstract available
    
    
23. BORDET C, Maachi O, Papeix AC, Laigo P, et al
    Human papillomavirus-related conditions in women with multiple sclerosis receiving disease-modifying therapies: A Pharmacovigilance disproportionality analysis from the WHO vigibase(R).
    Mult Scler. 2025 Oct 8:13524585251377411. doi: 10.1177/13524585251377411.
    PubMed         Abstract available
    
    
24. AJDINAJ P, Mongay-Ochoa N, Alberich M, Tintore M, et al
    Long-term impact of spinal cord reserve on disability accumulation in multiple sclerosis.
    Mult Scler. 2025 Oct 7:13524585251378995. doi: 10.1177/13524585251378995.
    PubMed         Abstract available
    
    

    
    Nat Rev Neurol

25. KIANI L
    Real-world effectiveness of stem cell transplantation for multiple sclerosis.
    Nat Rev Neurol. 2025 Oct 7. doi: 10.1038/s41582-025-01157.
    PubMed        
    
    

    
    Neurologia (Engl Ed)

26. ARRIAGADA OPAZO J, Farah Gonzalez V, Gonzalez Delgadillo M, Nunez-Franz L, et al
    Multiple Sclerosis mortality trend by sex: Chile 1997-2019.
    Neurologia (Engl Ed). 2025 Oct 6:S2173-5808(25)00098.
    PubMed         Abstract available
    
    
27. PINAR MORALES R, Guirado Ruiz PA, Barrero Hernandez FJ
    Impact of fatigue on quality of life in adults with relapsing-remitting multiple sclerosis.
    Neurologia (Engl Ed). 2025 Oct 7:S2173-5808(25)00101.
    PubMed         Abstract available
    
    

    
    Neurology

28. VILASECA A, Dalmau JO, Benarroch E
    What Are the Proposed Mechanisms Contributing to the Manifestations of Anti-NMDAR Encephalitis?
    Neurology. 2025;105:e214232.
    PubMed         Abstract available
    
    
29. TASHIRO T, Ogata H, Fukami Y, Maimaitijiang G, et al
    Clinical, Electrophysiologic, and Pathologic Features of Anti-Contactin-Associated Protein 1 Autoimmune Nodopathy.
    Neurology. 2025;105:e214143.
    PubMed         Abstract available
    
    

    
    PLoS One

30. AL-EITAN L, Ataa A
    Investigating genetic links of vitamin D metabolism pathway genes (CYP2R1, CYP27B1, CYP24A1, and DBP) in Multiple Sclerosis patients.
    PLoS One. 2025;20:e0333924.
    PubMed         Abstract available
    
    
31. YOSHIKAWA H, Adachi Y, Nakamura Y, Kuriyama N, et al
    Comparative study of Japanese nationwide epidemiological studies of myasthenia gravis using datasets of 2006 and 2018.
    PLoS One. 2025;20:e0334041.
    PubMed         Abstract available
    
    
32. CAMBIER A, Da Silva J, Bex J, Canesi F, et al
    Blockade of mTOR ameliorates IgA nephropathy by correcting CD89 and CD71 dysfunctions in humanized mice.
    PLoS One. 2025;20:e0318581.
    PubMed         Abstract available
    
    
33. SOLARI A, De Panfilis L, Zagarella RM, Ghirotto L, et al
    Advance care planning in multiple sclerosis (ConCure-SM): A multicenter single-arm pilot and feasibility study.
    PLoS One. 2025;20:e0331220.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge.